Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 13/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 13/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13175635 | 0.87 | MTNR1A (0.40) | MTNR1AMTNR1BKCNH2 | |
| SCHEMBL13175669 | 0.82 | RPS6KA3 (0.36) | KCNH2PIK3CDPIK3CAPIK3CBPIK3CG | |
| Hydrochloric Acid SCHEMBL2920921 | 0.81 | KCNH2 (0.35) | KCNH2PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL5740250 | 0.79 | KCNH2 (0.35) | KCNH2PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL2915126 | 0.79 | KCNH2 (0.36) | KCNH2 | |
| SCHEMBL2918405 | 0.78 | KCNH2 (0.38) | KCNH2 | |
| SCHEMBL3155066 | 0.78 | MAPK1 (0.44) | MTNR1AMTNR1BKCNH2 | |
| SCHEMBL2919816 | 0.77 | PDE10A (0.49) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL2916416 | 0.76 | KCNH2 (0.53) | KCNH2 | |
| SCHEMBL2925960 | 0.75 | AKT1 (0.42) | MTNR1AMTNR1BNAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1560488-B1 | ANTIBACTERIAL AGENTS | GLAXO GROUP LTD (GB) | 2010-09-01 | — | — | EP | disclosed |
| US-7618959-B2 | Antibacterial agents | SMITHKLINEBEECHAM CORP (US) | 2009-11-17 | — | — | US | disclosed |
| US-20070004710-A1 | Antibacterial agents | SMITHKLINE BEECHAM CORPORATION | 2007-01-04 | — | — | US | disclosed |
| EP-1560488-A4 | ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM CORP (US) | 2006-08-02 | — | — | EP | disclosed |
| EP-1560488-A2 | ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-10 | — | — | EP | disclosed |
| WO-2004041210-A2 | ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004710-A1 | Antibacterial agents | NQO2, NRDC, IFNG | MTNR1A 1750/4885MTNR1B 1729/4885KCNH2 3365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.